Vax

Pfizer and BioNTech say their COVID-19 vaccine is more than 90% effective (whoa)

Snacks / Monday, November 09, 2020

Biggest vax flex yet... Big pharma Pfizer and German biotech BioNTech said their jointly developed COVID-19 vaccine was more than 90% effective in Phase 3 trials — that's huge. For reference:

  • 50% to 60% effectiveness: Dr. Fauci has said this rate would be acceptable to approve a vaccine (the flu vaccine is only 40% to 60% effective).
  • 60% to 70%: Health experts say this rating would be a big win. Pfizer's 90%+ would be a wild success — but results are preliminary and haven't been peer-reviewed.

Please get it mRN-ASAP... If Pfizer's vax gets FDA-approval, it would be the 1st mRNA vaccine ever approved for human use. Unlike OG vaccines (which use a weakened virus to generate an immune response), mRNA ones teach cells to destroy the virus.

  • Moderna stock popped too because it's also in final stage trials of an mRNA vaccine. AstraZeneca, which is in final trials for a traditional vax, dropped.
  • Reopening stocks majorly soared: AMC was up 51%, Carnival was up 39%, and Delta spiked 17%. "Pandemic Winners" like Netflix, Peloton, and Zoom all dropped big.
  • BTW: Vaccines usually take around 10 years from development to approval. This vax is on pace for a record-shattering timeframe.

Pfizer has a big leg up... if others have to compete with a 90% efficacy rate — that's highly attractive to vax-buying countries, even though Pfizer's vax comes with more rollout challenges. Moderna seems the most likely to get similar results (because: #mRNAlife). Pfizer's planning to request FDA emergency use authorization in late November. With approval, Pfizer says it can make 50M doses in 2020 and 1.3B in 2021.

Get Your News

Subscribe and thrive

Snacks provides fresh takes on the financial news you need to start your day. Chartr provides data visualizations on business, entertainment, and society. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.